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ABSTRACT 
There is a growing socioeconomic recognition that clinical bone diseases such as bone infections, bone tumors and osteoporoti c bone loss mainly 
associated with ageing, are major issues in today0s society. SPARC (secreted protein, acidic and rich in cysteine), a matricellular glycoprotein, 
may be a promising therapeutic target for preventing or treating bone‐related diseases. In fact, SPARC is associated with tissue remodeling, 
repair, development, cell turnover, bone mineralization and may also participate in growth and progression of tumors, namely cancer‐related 
bone metastasis. Yet, the function of SPARC in such biological processes is poorly understood and controversial. The main objective of this work 
is to review the current knowledge related to the activity of SPARC in bone remodeling, tumorigenesis, and bone metastasis. Progres s in 
understanding SPARC biology may provide novel strategies for bone regeneration and the development of anti‐angiogenic, anti‐proliferative, or 
counter‐adhesive treatments specifically against bone metastasis.  
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SPARC (secreted protein, acidic and rich in cysteine), also termed 
osteonectin or BM‐40, is a major bone matrix non‐collagenous 
protein and a component of the extracellular matrix (ECM) of 
multiple tumor types. It is a member of a larger family of SPARC‐ 
related proteins that modulate cell interaction with the extracellular 
milieu [Termine et al., 1981]. SPARC is in matricellular class of 
secreted glycoproteins that exhibit counter‐adhesive effects that lead 
to cell developing round shape and other changes in cell morphology 
and disruption of cell–matrix interactions [Sweetwyne et al., 2004]. 
Other members of the SPARC family include testican‐1, ‐2, and ‐3, 
tsc 36 (transforming growth factor beta (TGF‐b) stimulated clone 36), 
SPARC‐like 1 also known as hevin/SC1 (synaptic cleft 1), Mast9 or 
ECM2, and SPARC‐related modular calcium‐binding (SMOC)‐1 and ‐ 
2 [Bradshaw, 2012]. 
SPARC, as a multifunctional calcium‐binding matricellular 
glycoprotein, participates in tissue remodeling, morphogenesis, and 
 
bone mineralization and is secreted by many different types of  
cells, such as osteoblasts, fibroblasts, endothelial cells, and  
platelets [Termine et al., 1981; Brekken and Sage, 2000; Alford and 
Hankenson, 2006]. 
SPARC is a single‐copy gene with a high degree of evolutionary 
conservation, with a molecular weight of 32.5 kDa that can be divided 
into three distinct modules as shown in Figure 1. 
Module I (NH2‐terminal) contains immune dominant epitopes and 
binds to hydroxyapatite (HA). The NH2‐terminal domain is an acidic 
region rich in asparagine (Asp) and glutamate (Glu), which can bind to 
5–8 calcium ions, through a different mechanism found in a large 
family of calcium‐binding proteins, the helix‐turn‐helix   structural 
domain (EF‐hand motifs). It is also the region that is the most distinct 
from other members of the SPARC gene  family. 
Module II, Cysteine‐rich, is homologous to a repeated domain in 
follistatin (FS). It contains bioactive peptides that exert different 
18 SPARC IN BONE REMODELING AND BONE METASTASIS JOURNAL OF CELLULAR BIOCHEMISTRY  
 
 
 
 
 
effects on endothelial cells. Peptide 2.1 with an identical structure to 
epidermal growth factor (EGF)‐like S hairpin, inhibits the prolifera- 
tion of endothelial cells. Peptide FS‐E, corresponds to EGF‐like 
module in FS domain of SPARC. It potently inhibits endothelial cell 
migration in vitro and angiogenesis in vivo in a conformation‐ 
dependent manner [Chlenski et al., 2004]. Peptide FS‐K has an 
inhibitory effect on endothelial proliferation. On the contrary, peptide 
2.3 has a stimulatory effect on endothelial cell proliferation and 
angiogenesis [Lane and Sage, 1994]. Additionally, the NH2‐terminal 
region of module II may bind to heparin or to proteoglycans 
[Hohenester et al., 1997]. Module III binds to extracellular Ca2þ ions 
through EF‐hand motifs. This module contains the peptide 4.2, which 
stimulates endothelial cells migration but inhibits their proliferation 
[Kupprion et al., 1998]. The fibril‐forming collagen types I, III, and V, 
and the basement membrane collagen type IV, bind to module III in a 
Ca2þ dependent fashion. Cleavage of SPARC by matrix metal- 
loproteinase 3 (MMP‐3) produces a peptide Z‐1 containing a Cu2þ 
binding sequence that exhibits a biphasic effect on endothelial cell 
proliferation and stimulates vascular growth. In contrast, peptides Z‐ 
2 and Z‐3 inhibit endothelial cells proliferation but stimulate their 
migration. Different regions of SPARC (designated peptides 1.1–4.2) 
are presented in Figure 2. 
In vitro experiments provided evidence that SPARC: 
(a). Has a counter‐adhesion effect on cells, since it disrupts cell 
adhesion to the ECM through its interaction with ECM 
components such as collagen  and  vitronectin  [Yan  and  
Sage, 1999]. 
(b). Promotes changes in cell morphology and cell differentiation 
[Yan and Sage, 1999]. 
(c). Inhibits cell cycle progression, namely by stalling cells in the G1 
phase of cell cycle [Funk and Sage, 1991; Tremble et al., 1993; 
Yang et al., 2007]. 
(d). Regulates the activity of growth factors, such as platelet‐derived 
growth factor (PDGF), fibroblast growth factor (FGF), or vascular 
endothelial growth factor (VEGF) [Kupprion et al., 1998; Yang 
et al., 2007]. 
(e). Regulates ECM and matrix metalloprotease production [Funk 
and Sage, 1991; Tremble et al., 1993]. 
(f). Strongly binds to type I collagen and synthetic HA and mediates 
mineralization of the type I collagen [Termine et al., 1981]. 
(g). Inhibits adipogenesis and promotes osteoblastogenesis [Nie and 
Sage, 2009]. 
In addition to the described functions in vitro, SPARC‐null mice 
are born with no obvious abnormalities, but shortly after birth these 
mice undergo progressive early‐onset cataractogenesis [Anselme and 
Bigerelle,  2005].  Thus,  the  SPARC  gene  is  required  for       lens 
transparency. 
Also SPARC‐null mice exhibit an increased accumulation of white 
adipose tissue (WAT) and show osteopenia. This fact based on in vitro 
studies could be a consequence of the up‐regulation of catenin  
signaling and altered regulation of collagen expression and 
deposition [Nie and Sage, 2009]. Interestingly, the  overproduction 
of SPARC by the adipose tissue of obese mice contributes to increased 
plasminogen activator inhibitor 1 (PAI‐1) levels in conditions 
associated with obesity. SPARC is highly related to body mass index 
as an autocrine and or/paracrine factor of the adipose tissue that may 
affect key functions of this tissue and may influence bone metabolism 
[Tartare‐Deckert et al., 2001]. 
Furthermore, SPARC controls important mechanisms involved in 
cancer development and progression. These include the regulation of 
the epithelial‐to‐mesenchymal transition (EMT), apoptosis, angio- 
genesis, and also the regulation of the inflammatory response. These 
mechanisms are relevant in the metastatic dissemination capacity of 
several cancer cells into bone tissue. However, the function of SPARC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Structure of human SPARC protein. A ribbon diagram derived from crystallographic data shows the three modular domains of SPARC. The follistatin‐like domain, aa 53– 
137 shown in red (except the peptide 2.1), aa 55–74, and the peptide 2.3 (aa 114–130) shown in green and black, respectively. Module III aa 138–286 is shown in blue (except the 
aa 255–274, peptide 4.2 shown in yellow). Adapted from Hohenester et al.  [1997]. 
  
 
in such phenomena is contradictory. SPARC seems to be a key factor 
in biological processes, such as bone remodeling, tumorigenesis, and 
bone metastasis due to all the activities performed by this protein 
in Figure 3. 
This review explores the correlation between SPARC expression/ 
function in bone remodeling and in tumorigenesis, particularly in 
cancer‐related bone metastasis. Ultimately, we aim to contribute 
towards filling a gap in the literature on the association of  SPARC 
with bone metastasis and encourage further research and progress on 
novel strategies for bone regeneration and the development of anti‐ 
angiogenic,  anti‐proliferative,  or  counter‐adhesive  treatments for 
metastatic bone tumors. 
 
 
SPARC  AND  BONE REMODELING 
Bone is a dynamic tissue that combines chemical, cellular, 
biophysical, and hormonal processes, which undergoes constant 
turnover. Modeling is a process that sculpts the shape and sizes of 
bone by the coordinated processes of bone formation and resorption. 
Modeling process is critical during growth but becomes relatively 
ineffective after skeleton maturity. Remodeling, on the other hand, is 
a process by which the skeleton is continuously renewed. It results in 
the turnover of lamellar bone without causing significant changes in 
bone quantity, geometry, or size. The purpose of remodeling is to 
adjust the skeleton to changes in mechanical demands, to prevent 
accumulation of fatigue damage, to repair microfractures, to ensure 
the viability of the osteocytes, and to allow the skeleton to participate 
in the mineral homeostasis [Walsh et al., 2003]. The bone resorption 
and formation cycle is a highly orchestrated process carried out by a 
multicellular unit, called the basic multicellular unit (BMU), which 
comprises osteoclasts and osteoblasts [Fauci and Longo, 2008]. The 
determinants of the coupling between bone resorption and formation 
are not known, but they may include the expression pattern of 
growth factors and/or proteins that vary spatially and temporally. 
These polypeptides mediate a number of physiological processes, 
such as immune response, regulation of hormone secretion, growth 
and cell differentiation, morphogenesis, the regeneration of tissues, 
as well as the induction and remodeling of bone [Alford and 
Hankenson, 2006]. 
SPARC binds to ECM proteins such as types I, III, IV, and V 
collagen, thrombospondin, PDGF‐AB, and PDGF‐BB. SPARC binds 
strongly to type I collagen  and synthetic HA  and can mediate the   
in  vitro  mineralization  of  type  I  collagen  [Termine  et  al., 1981]. 
It appears that SPARC has a role in connecting collagen fibers to HA 
crystals by a terminal sequence rich in amino acids. Attachment to 
collagen, however, has been reported both to promote and inhibit HA 
formation [Termine et al., 1981; Romberg et al., 1985; Romberg  
et al., 1986; Doi et al., 1989]. Infrared analysis of the mineral and 
matrix in bones of SPARC‐null mice revealed a decreased number of 
bone cells, leading to decreased bone formation and resorption, that 
could hinder the degradation and replacement of mature collagen, 
thereby  maintaining  collagen  crosslinks  [Boskey  et  al.,  2003]. 
Furthermore, a polyclonal anti‐SPARC antibody did not affect on 
mineralization thus, as previously suggested, SPARC may be more 
important  for  regulating  matrix  formation  than    mineralization 
[Boskey et al., 2008]. Crystal structure analysis and site‐directed 
mutagenesis within module III revealed that five residues R149, N156, 
L242, M245, and E246 are required for collagen binding. In addition, 
SPARC recognized the hydrophobic GVMGFO motif in collagen 
[Hohenester et al., 2008]. The conformational change that occurred in 
SPARC during collagen binding created a deep specificity pocket that 
was bound to the phenylalanine side chain of the GVMGFO motif. 
Yet, the functional importance of these structural alterations is still 
not understood. On the other hand, post‐translational modification of 
SPARC may be controlled in a tissue specific manner and potentially 
associated with functions of SPARC. Several reports indicated that 
SPARC participated in the regulation of collagen fibril assembly 
[Bradshaw et al., 2003; Wang et al., 2005]. More recently, it was 
shown that wild type matrices had thick collagen fibers organized 
into longitudinal bundles, whereas SPARC‐null matrices had thinner 
fibers in random networks [Kapinas et al., 2012]. Rentz et al. [2007] 
speculated that SPARC influenced procollagen processing by 
modulating integrin engagement and processes that affected collagen 
deposition and also improved matrix assembly. The functional 
significance of SPARC interaction with collagens in tissues is not 
clear. Collagen may serve as a storage site for SPARC in the ECM or 
might directly modulate the activity of SPARC. Interestingly enough, 
bone  and  platelet  SPARCs  have  patterns  of  glycosylation that 
appeared to affect collagen‐binding activity. Specifically, bone 
SPARC binds to types I, III, and V collagen and platelet SPARC has no 
apparent affinity for them [Kelm and Mann, 1991]. 
Some applications for SPARC have been explored in the 
development of advanced composite biomaterials for skeletal tissue 
regeneration. One example concerned the production of nano- 
hydroxyapatite/collagen/SPARC composites for bone graft applica- 
tions [Liao et al., 2009]. Others studies have used a glutamic acid‐rich 
peptide derived from SPARC, functionalized with an acrylate group 
for covalent attachment to the matrix that significantly increased the 
shear modulus of a bone‐mimetic hydrogel/apatite  nanocomposite 
 
 
 
 
 
 
 
 
Fig. 2.    The regions spanned by different SPARC peptides identified in various studies, adapted from Tai and Tang [2008]. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. SPARC is a key protein in bone remodeling, tumorigenesis, and bone metastasis and its activities associated to these biological processes are respectively indicated. 
 
 
and improved the dispersion of apatite nanoparticles in aqueous 
solution [Sarvestani et al., 2008]. 
 
 
SPARC  ACTIVITY  IN  CANCER BIOLOGY 
SPARC contributes to the disruption of cell adhesion to ECM by 
promoting morphologic changes in cell shape. SPARC also reduces 
the activity of several growth factors, including PDGF, VEGF, and 
bFGF. In addition, its ability to regulate matrix remodeling via  
metalloproteinases, together with its ability to inhibit G1 to S‐phase 
cell cycle progression in primary cells, suggests that SPARC might 
participate directly in tumor progression suppression [Funk and 
Sage, 1991; Tremble et al., 1993]. SPARC involvement with different 
tumors  is  reported  to  be  contextual  and  attributed  to  a  given 
microenvironment. Different expression patterns and activities of 
SPARC are depending on cancer type and upon whether it is 
expressed by malignant cells themselves or by neighboring stromal 
cells [Tai and Tang, 2008]. 
SPARC expression is associated with a favorable prognosis in 
some studies on human prostate cancer [Welsh et al., 2001; Lapointe 
et al., 2004; Wong et al., 2007]. In these studies SPARC may 
indeed function as a tumor suppressor since down‐regulation   and 
inactivation of SPARC gene expression enhanced aggressive   and 
metastatic behavior. On the other hand, SPARC can be described as 
a protumorigenic and prometastatic protein as found in studies of 
colorectal cancer [Porte et al., 1995]. Moreover, high SPARC 
expression might have utility as a prognostic marker in human  
breast cancer [Graham et al., 1997; Lakhani et al., 2005]. However, 
SPARC has been associated with metastasis of prostate cancer,  as 
 high levels of SPARC were found at sites of bone metastasis 
[Thomas et al., 2000]. Therefore the specific contribution of 
SPARC in tumor growth and progression is not clear [Arnold and 
Brekken,  2009].  Understanding  of  the  mechanisms    mediating 
SPARC0s   functions   in   each   different   cancer‐associated   process 
may clarify how this complex multifunctional protein functions in 
cancer. 
One of the important mechanisms involved in cancer develop- 
ment and progression is apoptosis. In fact, defects in apoptotic  
pathways  are  now  thought  to  contribute  to  tumor     initiation, 
progression, and metastasis. SPARC‐mediated apoptosis occurs by 
activating the expression of several members of extrinsic pathways of 
apoptosis such as caspase 3, caspase 8, caspase 10, and Fas‐associated 
protein with death domain (FADD). SPARC induced apoptosis   in 
ovarian carcinoma cells and enhanced the chemosensitivity of 
colorectal cancer cells when exposed to chemotherapy either alone or 
in combination with vitamin D [Yiu et al., 2001; Said and 
Motamed, 2005; Tai et al., 2005; Taghizadeh et al., 2007; Tang and 
Tai, 2007]. In contrast, the expression and activity of SPARC in 
human brain tumors promoted tumor invasion by reducing 
apoptosis and caspase activity of glioma cells through protein kinase 
B activation [Vajkoczy  et  al.,  2000;  Schultz  et  al.,  2002;  Shi 
et al., 2004]. 
In tumorigenesis, an invasive and metastatic phenotype is often 
acquired via induction of an epithelial‐mesenchymal transition (EMT) 
in which epithelial cells lose their polarity and develop a 
mesenchymal phenotype. This process is characterized by the  loss 
of intercellular adhesion (E‐ to N‐cadherin switch), down‐regulation 
of epithelial markers (cytokeratins), up‐regulation of mesenchymal 
markers (vimentin), and the acquisition of a fibroblast‐like motile and 
invasive phenotype. The transcription factor Snail and other members 
of its family have been implicated in the promotion of EMT [Cano 
et al., 2000; Moreno‐Bueno et al., 2006]. SPARC intervenes at several 
stages of EMT, thus contributing to malignant phenotype. For 
example, expression of SPARC in melanoma cells suppresses E‐ 
cadherin and increases N‐cadherin and vimentin expression through 
phosphorylation of focal adhesion kinase (FAK) and/or induction of 
Snail with the subsequent enhancement of cell migration and 
invasive capacity [Robert et al., 2006; Smit et al., 2007; Sosa      
et al., 2007]. SPARC might be involved in a collagen‐mediated EMT 
induction, since it induces collagen expression [Brekken et al., 2003; 
Prada et al., 2007; Sosa et al., 2007]. Moreover, SPARC was shown to 
modulate  cell  survival  and  invasion  of  glioma  cells  through   the 
activation of FAK and integrin‐linked kinase (ILK) [Shi et al., 2007]. 
Another cancer‐associated process is inflammation and SPARC 
likely plays a central role in this process, since its expression by 
malignant or stromal cells modulates the activity of growth factors 
and the capacity of inflammatory cells to infiltrate the tumor 
microenvironment. The suppression of SPARC expression in 
melanoma cells induced polymorphonuclear leukocyte (PMN) 
recruitment and inhibited tumor growth through a mechanism that 
involved the release of chemotactic factors such as interleukin 8 (IL‐8) 
and leukotrienes by inflammatory cells [Ledda et al., 1997; Alvarez 
et al., 2005]. 
SPARC has been implicated in angiogenesis, a process of 
neovascularization  that  is  critical  to  the  survival  of  tumors. In 
endothelial cells, SPARC is capable of inhibiting the activity of 
angiogenic growth factors VEGF, PDGF, and basic fibroblast growth 
factor (bFGF) [Kupprion et al., 1998]. Furthermore, in animal models 
of ovarian cancer, the absence of SPARC resulted in high expression 
of VEGF, VEGFR2, MMP‐2, and MMP‐9, thereby promoting the 
angiogenic and metastatic potential of these cancers [Said and 
Motamed, 2005; Said et al., 2007]. In neuroblastomas SPARC can 
function as an anti‐angiogenic factor produced by Schwann cells 
being its expression inversely correlated with tumor progression 
[Chlenski et al., 2002; Nie and Sage, 2009]. The role of SPARC in 
tumor angiogenesis is clearly dependent on the availability and  
activity of the intact protein, as well as its peptide fragments. For 
instance, peptides that include the KGHK‐Cu2þ motif, stimulated 
endothelial cell cycle and angiogenesis in vivo [Sage et al., 2003]. On 
the contrary, FS‐E peptide, inhibited angiogenesis associated with 
neuroblastoma, even in the presence of bFGF‐stimulation [Chlenski 
et al., 2004, 2010]. 
 
 
SPARC AND CANCER‐RELATED BONE METASTASIS 
During tumor progression, malignant cells, initiate a process of 
attachment and subsequent degradation of nearby stroma, leading 
finally to the establishment of metastatic foci in specific tissues, such 
as lung, bone, liver, or brain [Liotta and Kohn, 2001]. This contributes 
to the success of the tumor and consequently to poorer prognosis for 
patients. 
Bone metastases result when cancer cells spread from their site of 
origin (primary tumor) and settle in a bone to form a secondary 
cancer. This can affect only one area of the bone or several areas at 
any one time; complications of bone metastases include pain, 
increased risk of facture, hypercalcemia (abnormally high levels of 
calcium in the blood), and a decreased blood cell count. The most 
common cancer types that show tendency to metastasize in bone 
include prostate, breast, lung, kidney, thyroid cancer, and multiple 
myeloma. One of the consequences of bone metastases results from a 
decrease of osteoblast number. Having reached the bone, malignant 
cells disrupt the remodeling process that normally occurs. Osteoclast 
number increase as tumor cells secrete factors such as parathyroid 
hormone related protein (PTHrP) that stimulates bone resorption and 
therefore gradually destroy it. This in turn results in the release  of 
breakdown products such as TGF‐b which stimulates the growth of 
malignant cells, thus perpetuating the destructive cycle and 
enhancing localized tumor growth. Recently improved understanding 
of these biochemical processes has prompted investigation into  
whether skeletal events in patients with malignant bone disease may 
correlate with levels of serum and urine markers of bone turnover, 
thus facilitating earlier detection or screening for such events. More 
than 90% of all metastases are found in the back, pelvis, upper leg, 
ribs, upper arm, and skull. The prognosis of cancers that metastasize 
to bone is in general very poor and the treatment for bone metastases 
tend to minimize the symptoms by reducing pain and the risk of 
fracture. The prevention and the development of therapeutic 
strategies against metastatic bone tumors lie in understanding the 
malignant cells preference in certain cancer types (prostate, breast, 
lung, kidney, thyroid cancer, or multiple myeloma) to metastasize in 
 bone tissue. Bone microenvironment may provide growth stimulating 
factors or others proteins that induce proliferation and angiogenesis 
of cancer cells allowing them to arrest the bone tissue. SPARC has 
been shown by several studies to be a key protein that attracts prostate 
cancer cells to bone microenvironment [Jacob et al., 1999; De      
et al., 2003; Donahue, 2004]. One study showed that prostate cancer 
cells preferably migrated towards wild type bone extracts when 
compared to extracts obtained from SPARC null mice. This effect was 
reversed by restoration of SPARC [De et al., 2003]. The up‐regulation 
of VEGF production by SPARC via avb3 and avb5 is a  prostate 
cancer specific phenomenon, providing prostate cancer cells with 
significant growth advantage in bone [Donahue, 2004]. Other work 
indicates that p45‐sErbB3 (a soluble form of ErbB3, pooled in bone 
marrow supernatant samples from men with prostate cancer that had 
metastasized to bone) enhances the invasiveness of prostate cancer 
cells in part by stimulating the secretion of SPARC by bone. Thus p45‐ 
sErbB3 may mediate the bidirectional interactions between prostate 
cancer cells and bone [Chen et al., 2007]. 
The development and progression of bone metastatic prostate 
cancer using SPARC‐deficient mice infected with RM1 mouse 
prostate  cancer  cells  showed  that  bone  stromal  SPARC  inhibited 
prostate cancer expansion in bone through the regulation of 
osteoclast maturation and function [McCabe et al., 2011]. Another 
report, by Podgorski et al. [2009], suggested that cathepsin K 
modulates the biological activity of SPARC in prostate cancer bone 
metastasis by cleaving it. In two tumor bone metastases cell lines 
(derived from clinical, PC3, and experimental MDA‐231BO) enzy- 
matic processing of SPARC was reduced by inhibition of cathepsin K. 
Moreover the presence of a cathepsin inhibitor reduces the GRO 
(growth‐regulated oncogene) secretion, a pro‐inflammatory and 
chemotactic factor regulated by SPARC. On the other hand, SPARC 
and cathepsin K overexpression and secretion raised GRO secretion 
[Podgorski et al., 2009]. 
In a recent study the effect of bone matrix SPARC on PC3 behavior 
was assessed by using murine osteoblast to create normal and 
SPARC‐null bone matrix in vitro. The results of this study showed 
that when PC3 cells were grown on the wild type matrices, they 
presented decreased cell proliferation, increased cell spreading, and 
decreased resistance to radiation‐induced cell death, compared to 
cells grown on SPARC null‐matrix [Kapinas et al., 2012]. DeRosa et al. 
[2012] recently showed that SPARC gene was highlighted as a 
potential early marker of poorly differentiated phenotype of prostate 
cancers and the high SPARC expression at the time of prostatectomy 
was associated with the development of metastasis. 
Based on the two separate transgenic models of prostate and breast 
cancer (transgenic adenocarcinoma of the mouse prostate and 
murine mammary tumor virus polyomamiddle T, respectively), using 
SPARC-/- and SPARCþ/-  mice, found that loss of SPARC had no 
significant impact on tumorigenesis [Wong et al., 2008]. Although the 
loss of SPARC, by itself, neither directly promoted nor inhibited 
spontaneous prostate or breast cancer progression, SPARC expression 
could be used as a potential prognostic biomarker of tumor severity 
and/or aggressiveness. 
SPARC might have an indirect effect on breast cancer cell 
metastasis in bone since its isolation from several sources such as 
osteoblasts or epithelial cells stimulated motility of human   breast 
cancer cells and also enhanced the chemoattraction of breast cancer 
cells toward vitronectin (a known chemoattractant protein) 
[McKnight et al., 2006]. In another study a breast cancer cell   line 
(MDA‐231) deficient of SPARC was used in order to determine the 
endogenous effect of SPARC expression on invasion and metastasis 
of the breast malignant cells in bone. The induction of SPARC  
expression in MDA‐231 cells did not affect the proliferation, 
apoptosis, aggregation, or cell migration, but inhibited tumor cell 
invasion in vitro. Moreover, high expression of SPARC inhibited 
metastasis to different organs including lung and bone. Exogenous 
SPARC inhibited the platelet aggregation in vitro and the high  
expression of this protein in MDA‐231 cells reduced tumor cell‐ 
induced thrombocytopenia in vivo in relation with control. In 
conclusion, a high endogenous SPARC expression seems to inhibit 
MDA‐231 breast cancer metastasis by reducing the invasion activity 
and tumor cell‐platelet aggregation [Koblinski et al., 2005]. 
As already mentioned, the survival rate in the case of patients 
with bone metastasis is very low. The understanding of cancer  
metastasis to bone should help the prevention of metastasis and the 
establishment of a valid therapy in order to improve the patient0s life 
quality and may increase survival rates. It has been described that 
SPARC is associated to tumorigenicity and metastasis of cancer‐ 
related  bone  metastasis  like  lung  or  melanoma  cancers   [Kato 
et al., 2000; Zhou et al., 2010]. Nevertheless, there are only few 
studies regarding prostate and breast cancers that tried to disclose   
the roles of SPARC in bone metastasis (Table I), and none associated 
with other cancer types that show a tendency to develop bone 
metastasis. 
 
 
CONCLUSIONS  AND  PERSPECTIVES 
 
Considerable attempts have been made to produce adequate matrices 
or scaffolds that mimic bone ECM for applications in tissue 
engineering and regenerative medicine. In this context, several  
factors must be considered, such as the modification of biomaterial 
surfaces using growth factors, living bone cells or proteins, to guide 
cellular responses in bone remodeling, like osteoblast adhesion and 
long‐term  functionality  expressed  as  proliferation,  synthesis  of 
alkaline phosphatase, and deposition of calcium containing mineral 
[Manuel et al., 2003]. SPARC, a matricellular glycoprotein associated 
with tissue remodeling, repair, development, cell turnover, is involved 
in bone formation, bone initiating mineralization process, and 
collagen fibril assembly [Termine et al., 1981; Doi et al., 1989; 
Bradshaw et al., 2003; Wang et al., 2005; Kapinas et al., 2012]. The 
application of this protein could benefit the development of new valid 
therapeutic strategies for skeletal tissue regeneration. In addition, the 
research in this topic is essential since there are very few works 
involving SPARC and biomaterials for bone tissue regeneration 
[Sarvestani et al., 2008; Liao et al., 2009]. 
Furthermore, SPARC controls important mechanisms involved in 
cancer development and progression including the regulation of 
epithelial‐to‐mesenchymal transition, apoptosis, angiogenesis, and 
also the regulation of the inflammatory response. SPARC is relevant 
in metastatic dissemination capacity of prostate, breast, lung, kidney, 
thyroid cancer, and multiple myeloma cancer cells into bone tissue. 
 TABLE  I. Studies Related  to SPARC Activity in  Bone  Metastasis 
 
Tumor type Expression Experimental approach Activity Refs. 
Prostate High levels of SPARC at sites 
of bone metastasis 
 
 
High expression of SPARC in 
metastatic prostate cancer 
 
 
 
 
SPARC expression is increased 
in prostate cancer 
metastases 
 
A low glycosylated SPARC is 
highly abundant in  bone 
 
 
 
 
p45‐sErbB3 up‐regulated the 
expression of SPARC 
 
Higher SPARC expression in 
bone metastasis compared 
to primary tumor 
Human prostate cancer cell lines 
LNCaP, LNCaP‐C4–2, PC3, and 
lacZ‐transfected CWR22R 
(H‐clones) SPARC‐null mouse 
model 
Transcriptomes of laser 
capture‐micro‐dissected tumor 
cells with well‐ and poorly 
differentiated (PD) phenotype 
from primary prostate tumors of 
patients with 78 months of mean 
follow‐up after radical 
prostatectomy. 
In vitro system composed by PC3 
and mineralized matrices 
synthetized by wild type and 
SPARC‐null osteoblasts. 
In vitro studies using human 
prostate cancer cell lines (DU‐145 
and PC‐3), several human 
prostate epithelial cell lines as 
well as a HT1080 fibrosarcoma 
cell line and a B16‐F10 mouse 
melanoma cell and extracts from 
various organs of mice and rat 
Human prostate cancer cell lines 
(LNCaP and PC‐3) 
SPARC deficient mice infected with 
SPARC‐expressing syngeneic 
RM1 mouse prostate cancer  cells 
Attracts prostate cancer cells to 
bone; Increases VEGF production 
by metastatic cancer cells and 
integrin activation 
High SPARC expression at the time 
of radical prostatectomy is 
associated with an increased risk 
of tumor metastasis. SPARC gene 
was identified as a potential early 
marker of less favorable outcome 
associated with PD of prostate 
cancers. 
Bone matrix‐associated SPARC 
attenuated the growth of PC3, 
increased cell spreading, and 
increased their sensitivity to 
ionization radiation. 
Enhances the invasion and 
migration by prostate cancer 
cells; Chemoattractant for 
bone‐metastasizing epithelial 
cells; Enhances matrix 
metalloprotease activity in 
prostate cancer cells 
 
Enhances the invasiveness of the 
prostate cancer cell lines PC‐3 
and C4‐2B 
Inhibits prostate cancer expansion 
in bone through the regulation of 
osteoclast maturation and 
function 
De et al. [2003] 
 
 
DeRosa et al. [2012] 
 
 
 
 
Kapinas et al.  [2012] 
 
 
Jacob et al. [1999] 
 
 
 
 
Chen et al. [2007] 
McCabe et al. [2011] 
Breast In vitro MDA‐231 breast carcinoma 
cell line study applying SPARC 
derived from several sources 
(MDA‐MB‐435, MDA‐MB‐468), 
osteoblasts (hFOB1.19), 
non‐neoplastic breast epithelial 
(hTERT‐HME1), and vascular 
endothelial cells isolated from a 
bone biopsy (HBME‐1) 
Enhances breast cancer cells 
chemoattraction toward 
vitronectin 
McKnight et al. [2006] 
High SPARC expression in 
MDA‐231 cells 
 
 
 
 
 
 
Prostate/breast SPARC is significantly 
down‐regulated in highly 
metastatic human prostate 
cancer cells 
 
 
Up‐regulation of SPARC both 
in vivo in experimental 
prostate bone tumors, and 
in vitro in co‐cultures of 
bone marrow stromal cells 
with PC3 prostate 
carcinoma cells 
In vitro human cell line study using 
SPARC‐negative MDA‐231 breast 
carcinoma cell line infected with 
an adenovirus expressing SPARC; 
In  vivo nude  mouse model 
 
 
 
 
SPARCþ/- and SPARC-/- mice 
using two separate transgenic 
mouse tumor models: transgenic 
adenocarcinoma of the mouse 
prostate (TRAMP) and murine 
mammary tumor virus polyoma 
middle T (MMTV‐PyMT) 
In vitro co‐cultures of bone marrow 
stromal cells with prostate (PC3) 
and breast carcinoma cells 
(MDA‐231BO) Severe combined 
immunodeficient (SCID) mice 
human/intrabone model 
No effect on MDA‐231  cell 
proliferation, apoptosis, cell 
aggregation, or migration; 
Inhibits breast cancer metastasis 
by reducing the invasion activity 
and tumor cell platelet 
aggregation in vitro; Reduces 
tumor cell‐induced 
thrombocytopenia in vivo 
compared with control‐infected 
cells 
No effect on prostate or breast 
cancer with the mouse tumor 
models tested Useful biomarker of 
aggressive, metastasis‐prone 
tumors 
 
Bone marrow cathepsin K regulates 
the biological activity of SPARC 
in  prostate  cancer  bone 
metastasis 
Koblinski et al. [2005] 
 
 
 
 
 
 
Wong et al. [2008] 
 
 
 
 
Podgorski et al. [2009] 
 
 
 
Yet, the actual function of SPARC in tumorigenesis and tumor 
progression is still contradictory and not fully understood. There is 
not any review article addressing SPARC and cancer‐related bone 
metastasis. Depending on cancer type, different expression patterns 
and activities of SPARC may be found. This could be explained by the 
distinct tumor microenvironment established in different types   of 
cancers that translates in terms of local composition of matrix 
molecules and cytokines and the protease profile. The different  
proteolytic products (peptide fragments) corresponding to different 
regions of SPARC have distinct activities and may explain the  
divergent and inconsistent biological activities observed with native 
full‐size SPARC protein in distinct malignancies. SPARC  peptide 
 models  could  be  a  valid  strategy  to  understand  SPARC0s  specific 
action in mechanisms that occur in tumor invasion and metastasis in 
bone tissue. Very few attempts, including SPARC peptides combined 
with chemotherapy and/or drugs, have been performed in this 
direction up  to  now  [Chlenski  et  al.,  2004,  2010;  Gradishar  
et al., 2005; Von Hoff et al., 2008; Inoue et al., 2010]. 
Furthermore, the differential function of SPARC in several types of 
cancers might be dependent upon whether it is expressed by the 
malignant cells themselves or by neighboring stromal cells. A series of 
studies have been performed in an attempt to elucidate the actual role 
of SPARC produced  by  non‐malignant  stromal  cells  [Brekken 
et al., 2003; Sangaletti et al., 2003; Haber et al., 2008]. SPARC 
knock‐out   mice   showed   low   turnover   osteopenia   [Nie  and 
Sage,  2009],  intensive  osteoclastogenesis  [McCabe  et  al.,   2011], 
and matrices composed by thinner collagen fibers in random 
networks [Kapinas et al., 2012] that translated a less stroma and 
collagen deposition. It was proposed that SPARC is a critical 
component in the orchestration of the tissue microenvironment, 
important for metastatic cancer cells to grow and survive in the 
skeleton (skeletal cancer metastasis). In fact, the expression of many 
bone‐enriched proteins, including SPARC by stromal cells in normal 
prostate and the up‐regulation of VEGF production by SPARC being a 
prostate cancer specific phenomenon, contributes to the preference 
and significant growth advantage in bone‐like environment by 
prostate cancer cells. Also the association between SPARC expression 
pattern and malignancy of prostate and breast cancers may 
contribute to the use of SPARC as a potential prognostic biomarker 
of tumor severity and/or metastasis [Wong et al., 2008; DeRosa    
et al., 2012]. 
According to the works related to bone metastasis and presented in 
Table I, SPARC acts as protumorigenic and prometastatic protein, 
when expressed by stromal cells, trough enhancement of metal- 
loprotease activity, VEGF production, or chemoattraction toward 
vitronectin [Jacob et al., 1999; De et al., 2003; McKnight et al., 2006; 
Chen et al., 2007; DeRosa et al., 2012]. On the contrary, when SPARC 
is produced by malignant cells, it inhibits cancer expansion through 
regulation of osteoclast maturation/function or by reducing platelet 
aggregation. The final outcome of SPARC function will undoubtedly 
be highly context dependent [Framson and Sage, 2004]. The 
development of SPARC‐peptide models, conditional/gene inactiva- 
tion models [Ledda et al., 1997; Briggs et al., 2002; Smit et al., 2007] or 
the transcriptional targeting using SPARC promoter [Sato et al., 2003; 
Suzuki et al., 2005; Kelly et al., 2006; Lopez et al., 2006; Yang    
et al., 2007; Cheetham et al., 2008] could be a valid strategy to 
understand how SPARC influences tumor invasion and metastasis 
and may lead to the development of anti‐angiogenic, proliferation or 
counter‐adhesive  therapeutic  treatment  against  metastatic   bone 
tumors. 
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